THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, June 03, 2021
Lars Holtug elects as a member of Evaxion Biotech’s Board of Directors.
FREMONT, CA: Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, declares its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The voting took place during the General Meeting of Evaxions on 25 May 2021. Lars Holtug will also lead the Audit Committee for Evaxions and will take over from Mr. Boudreau.
Marianne S¸gaard, Chairwoman of Evaxion, says, “I am delighted to welcome Lars Holtug to the Evaxion Board of Directors. Lars brings a wealth of experience from senior roles in accountancy and Board memberships in numerous companies. He has spent significant time in the biotech industry, both in his role at PwC and as a Board member, and this experience will prove invaluable to Evaxion as we continue to advance our clinical programs to treat cancer, bacterial diseases and viral infections.”
Lars Holtug served in Denmark, including four years as chairman of the Board, employee, and PwC Partner for 35 years. Several Danish pharmaceutical and biotech businesses were among their clientele. He also advised management compensation boards and executives. He also assists the board of directors of many companies, including Gaming Investment A/S and MTI Caretag Invest A/S, both Chairman and a member of the board and the U.S. publicly traded firm Ascendis Pharma A/S, listed on the NASDAQ.
Evaxion Biotech A/S is a platform for developing new immunotherapies to treat cancer, bacterial illnesses, and viral infections in a human immune system, decoding and developing new immunotherapy. Based on its own and scalable core AI-immunology. Evaxion also promotes a portfolio of vaccinations for the prevention of pre-clinical bacterial and viral illnesses.
More in News